Extended Data Fig. 8: Mass spectrometry-based proteomics analyses of hypothalamic nuclei in response to GLP-1–MK-801.
From: GLP-1-directed NMDA receptor antagonism for obesity treatment
a-g, Proteomics data from study in Fig. 3h, i of mice treated with 100 nmol kg−1 MK-801 (n = 8 mice and n = 4 cages), 100 nmol kg−1 GLP-1 (n = 8 mice and n = 4 cages), 100 nmol kg−1 GLP-1–MK-801 (n = 8 mice and n = 4 cages) or vehicle (isotonic saline, n = 8 mice and n = 4 cages) for 5 days. a, Change in body weight. b, Cumulative food intake. c, Top twelve cellular component and top nine biological process ontologies identified using gene set enrichment (GSEA) analysis. d, Venn diagram showing the overlap between the SynGO database and the 506 uniquely differentially expressed proteins in response to GLP-1–MK-801. e, Sunburst plot of differentially expressed proteins belonging to cellular component functional terms computed with SynGO. Enrichment is colour coded by Q value for the functional terms. All level terms identified have been labelled. f, Sunburst plot of differentially expressed proteins belonging to biological process functional terms computed with SynGO. Enrichment is colour coded by Q value for the functional terms. All level terms identified have been labelled. g, Top ten SynGO enriched functional terms for cellular component and biological process. Data analysed by two-way repeated measures ANOVA to assess main effects of treatment (a and b). Benjamini-Hochberg corrected P (c-g) Data represents mean ± SEM; ****P < 0.0001. Detailed statistics are in Supplementary Table 1. The diagram in d was created using BioRender.